Interviews with Three Key Opinion Leaders
European Medical Journal articleAdverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis.
PosterHigh burden of disease for AAV patients in Germany - a claims study.
PosterRenal damage in ANCA-associated vasculitis in incident and relapsing patients.
Slide deckEconomic burden of ANCA-associated vasculitis in Germany - a claims data study.
PosterAdverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases.
PosterSeverity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data.
PosterComorbidity, adverse events and infections are major concerns in real world management of ANCA-associated vasculitis.
Abstract PosterVariable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients.
PosterManagement of ANCA-associated vasculitis in the UK: a complex pathway of patient referral, diagnosis, and treatment.
PosterPatient Experience in ANCA-Associated Vasculitis - Challenges from Diagnosis and Need for New Approaches.
Abstract PosterPatients with Relapsing ANCA-Associated Vasculitis (AAV) Experience Unmet Needs around Remission Induction and Therapy Related Adverse Events.
Abstract PosterReal World Experience in ANCA-Associated Vasculitis (AAV) – A Complex Pathway of Patient Referral, Diagnosis, and Management.
Abstract PosterAAV is a rare, severe small vessel vasculitis that affects multiple organs and has a high acute mortality risk
The interaction between the activated alternative complement pathway, neutrophils and C5a is at the heart of vasculitic damage in AAV
Treatment has improved but treatment-related complications remain common
Take the interactive challenge to assess your understanding of AAV. Fully interactive version available on desktop only
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis
Watts RA, et al. Nephrol Dial Transplant 2015;30(Suppl 1):i14–22.
Omerod AS, Cook MC. Intern Med J 2008;38(11):816–23.
Watts RA, et al. Arthritis Rheum 2000;43(2):414–9.
Watts RA, et al. Rheumatology (Oxford) 2012;51(5):926–31.
Watts RA, et al. Rheumatology (Oxford) 2017;56(9):1439–40.
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear, nose and throat; ESRD, end-stage renal disease; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; RRT, renal replacement therapy
*AAV patients with (n=212; mean age: 58 years; PR3-ANCA positive: n=138; MPO-ANCA positive: n=65; ANCA negative: n=9) and without (n=61; mean age: 52 years) renal involvement (active urinary sediment, proteinuria, impaired renal function or biopsy) diagnosed and treated with AAV at a single centre in the Netherlands between January 1990 and December 2007 who were followed until death, loss to follow-up, or December 2010;4 †Retrospective data collected from patients (n=72; mean age: 64 years) with a clinical AAV diagnosis (Chapel Hill disease definitions and PR3-/MPO-ANCA positive) and renal involvement at diagnosis (rise in serum creatinine >30% and/or erythrocyturia [≥10 red blood cells per high-power field and/or red blood cell casts]) in a single-centre cohort (Northwest Clinics, the Netherlands) between 1 February 2005 and 1 February 2015.5
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34.
De Joode AAE, et al. Clin J Am Soc Nephrol 2013;8(10):1709–17.
Houben E, et al. BMC Nephrol 2017;18(1):378.
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EUVAS, European Vasculitis Study Group; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RCT, randomised controlled trial; UK, United Kingdom
*Patients (n=524) with newly diagnosed GPA or MPA (adapted Chapel Hill disease definitions) recruited into four EUVAS RCTs in 42 hospitals in 11 European countries and Mexico between 1995 and 2005, and followed for 1 year;1 †Patients (n=535; median age: 61 years) with newly diagnosed GPA (53%) or MPA (47%; adapted 1994 Chapel Hill disease definitions, clinical presentation, and positive ANCA serology and/or histology) recruited into four EUVAS RCTs in 70 general and university hospitals in 15 countries between 1995 and 2002 with a median 5.16 years of follow-up for all patients. A control cohort was matched for age, sex, year and country;2 ‡Data collected from patients with a first diagnosis of incident GPA (n=465; mean age: 60.3 years) and non-GPA matched (sex, age, year of birth, and GPA diagnosis year) controls (n=4613: mean age: 60.3 years) from the UK (The Health Improvement Network) between 1992 and 2013, and divided into two cohorts based on the year of diagnosis (1992–2002 and
2003–2013).3
Little MA, et al. Ann Rheum Dis 2010;69(6):1036−43.
Flossmann O, et al. Ann Rheum Dis 2011;70(3):488–94.
Wallace ZS, et al. Semin Arthritis Rheum 2016;45(4):483–9.
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; BMI, body mass index; COPD, chronic obstructive pulmonary disease; EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear nose and throat; EU, European Union; GP, general practitioner; GPA, granulomatosis with polyangiitis; HIV, human immunodeficiency virus; ICU, intensive care unit; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3
*Retrospective study reviewing 929 incident AAV patients (GPA: 54%; MPA: 46%; mean age: 57 years; male: 53.7%) from four EU countries (399 physicians) who initiated remission induction therapy between November 2014 and February 2017 with data collected at baseline presentation, and after 1, 3, 6 and 12 months of treatment.1
Rutherford PA, et al. Real world experience in ANCA-associated vasculitis (AAV) – a complex pathway of patient referral, diagnosis, and management. Poster presented at: ASN 2018, 23–28 October 2018, San Diego, CA, USA (abstract SA-PO403).
Yates M, Watts R. Clin Med (Lond) 2017;17(1):60–4.
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34.
Chen M, et al. Medicine (Baltimore) 2008;87(4):203–9.
Lionaki S, et al. Arthritis Rheum 2012;64(10):3452–62.
ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear, nose and throat; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
Watts RA, et al. Nephrol Dial Transplant 2015;30(Suppl 1):i14–22.
Mansi IA, et al. Am Fam Physician 2002;65(8):1615–20.
16-17 October 2019 | Warsaw, Poland
5-10 November 2019 | Washington
8-13 November 2019 | Atlanta, Georgia
5 – 16 May 2020 | Stockholm, Sweden
Are you a healthcare professional outside of the US?
Yes, I am a healthcare professional outside of the US
I am not a healthcare professional
If you are an ANCA-associated vasculitis patient or carer please visit https://www.myancavasculitis.com/
